Positive topline results for GlycoMimetics' sickle cell drug
This article was originally published in Scrip
Executive Summary
Patients with sickle cell disease who were treated with GlycoMimetics' pan-selectin antagonist GMI-1070 experienced reductions in the duration of vaso-occlusive crisis (VOC), the length of associated hospital stays and the use of narcotic pain relief in a Phase II study with 76 people.